Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Differential expression of wild-type and mutant NMMHC-IIA polypeptides in blood cells suggests cell-specific regulation mechanisms in MYH9 disorders.

Blood - 15 Mar 2008

Kunishima Shinji, Hamaguchi Motohiro, Saito Hidehiko

Abstract excerpt

MYH9 disorders such as May-Hegglin anomaly are characterized by macrothrombocytopenia and cytoplasmic granulocyte inclusion bodies that result from mutations in MYH9, the gene for nonmuscle myosin heavy chain-IIA (NMMHC-IIA). We examined the expression of mutant NMMHC-IIA polypeptide in peripheral blood cells from patients with MYH9 5770delG and 5818delG mutations. A specific antibody to mutant NMMHC-IIA (NT629)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies
Share to Antibody Specificity

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Cells

Share to Hematologic Diseases

Share to Inclusion Bodies

Share to Megakaryocytes

Share to Molecular Motor Proteins

Share to Myosin Heavy Chains

Source

Identifiers

PMID: 18192507
DOI: 10.1182/blood-2007-10-116194

Genes

MYH9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Differential expression of wild-type and mutant NMMHC-IIA polypeptides in blood cells suggests cell-specific regulation mechanisms in MYH9 disorders.PMID 18192507Read ↗

Pathogenetic mechanisms of hematological abnormalities of patients with MYH9 mutations.Semantic proximity Read ↗

[May-Hegglin anomaly: past and present--novel diagnostic test and new concept of the disease].Semantic proximity Read ↗

Immunofluorescence analysis of neutrophil nonmuscle myosin heavy chain-A in MYH9 disorders: association of subcellular localization with MYH9 mutations.Semantic proximity Read ↗

Immunocytochemistry for the heavy chain of the non-muscle myosin IIA as a diagnostic tool for MYH9-related disorders.Semantic proximity Read ↗

MYH-9 Related Platelet Disorders: Strategies for Management and DiagnosisSemantic proximity Read ↗

Mutations in the NMMHC-A gene cause autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly/Sebastian syndrome).Semantic proximity Read ↗

MYH9-Related Platelet DisordersSemantic proximity Read ↗

Advances in the understanding of MYH9 disorders.Semantic proximity Read ↗

[May-Hegglin anomaly--from genome research to clinical laboratory].Semantic proximity Read ↗

Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.Semantic proximity Read ↗

Clinical, pathological, and genetic analysis of ten patients with MYH9-related disease.Semantic proximity Read ↗

MYH9 disorder: Identification and a novel mutation in patients with macrothrombocytopenia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.